[{"id":"269bcf7a-a222-4eb1-a733-a5c181aede05","acronym":"SURPASS-3","url":"https://clinicaltrials.gov/study/NCT05601752","created_at":"2022-11-05T15:14:24.529Z","updated_at":"2024-07-02T16:34:25.911Z","phase":"Phase 2","brief_title":"ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)","source_id_and_acronym":"NCT05601752 - SURPASS-3","lead_sponsor":"Adaptimmune","biomarkers":" HLA-A • BRCA • PARP1 • MAGEA4","pipe":" | ","alterations":" HLA-A*02:01 • HLA-A*02 • BRCA mutation • HLA-A2 positive • MAGEA4 expression","tags":["HLA-A • BRCA • PARP1 • MAGEA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • HLA-A*02 • BRCA mutation • HLA-A2 positive • MAGEA4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • uzatresgene autoleucel (ADP-A2M4CD8)"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 06/26/2023","start_date":" 06/26/2023","primary_txt":" Primary completion: 08/12/2026","primary_completion_date":" 08/12/2026","study_txt":" Completion: 08/12/2026","study_completion_date":" 08/12/2026","last_update_posted":"2024-06-14"},{"id":"fc2b490f-716a-4fb8-8ba2-7e656cf95939","acronym":"SURPASS","url":"https://clinicaltrials.gov/study/NCT04044859","created_at":"2021-01-18T19:50:41.997Z","updated_at":"2024-07-02T16:35:19.014Z","phase":"Phase 1","brief_title":"ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)","source_id_and_acronym":"NCT04044859 - SURPASS","lead_sponsor":"Adaptimmune","biomarkers":" HLA-A • MAGEA4","pipe":" | ","alterations":" HLA-A*02 • MAGEA4 expression","tags":["HLA-A • MAGEA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • MAGEA4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecelra (afamitresgene autoleucel) • uzatresgene autoleucel (ADP-A2M4CD8)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 08/20/2019","start_date":" 08/20/2019","primary_txt":" Primary completion: 12/23/2025","primary_completion_date":" 12/23/2025","study_txt":" Completion: 04/30/2037","study_completion_date":" 04/30/2037","last_update_posted":"2024-02-16"}]